Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
DOD Biotech PCLBKK:DOD-R -5.84%67 Capex-to-Operating-Cash-Flow is 0.11 as of Jun. 2026, which is 83% below its 10-year median of 0.63. GuruFocus rates BKK:DOD-R with a GF Score™ of 67/100 and a GF Value™ of ฿1.52. The stock has 6 warning signs investors should review. Among 1,157 Consumer Packaged Goods companies, DOD Biotech PCL ranks worse than 86430.34% on this metric.
Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.
DOD Biotech PCL (BKK:DOD-R) Capex-to-Operating-Cash-Flow Explanation
Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.
Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.
DOD Biotech PCL Capex-to-Operating-Cash-Flow Related Terms
DOD Biotech PCL Capex-to-Operating-Cash-Flow Historical Data
* Premium members only.
The historical data trend for DOD Biotech PCL's Capex-to-Operating-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DOD Biotech PCL Capex-to-Operating-Cash-Flow Chart
BKK:DOD-R vs KHC, GIS: Capex-to-Operating-Cash-Flow Comparison
For the Packaged Foods subindustry, DOD Biotech PCL's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DOD Biotech PCL Capex-to-Operating-Cash-Flow vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, DOD Biotech PCL's Capex-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where DOD Biotech PCL's Capex-to-Operating-Cash-Flow falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Capex-to-Operating-Cash-Flow of 0.11 mean?
DOD Biotech PCL (BKK:DOD-R) has a Capex-to-Operating-Cash-Flow of 0.11 as of Jun. 2026. Capex to Operating Cash Flow ratio assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. View historical data on DOD Biotech PCL and its competitors. This is 83% below median its historical median of 0.63. Over the past decade, DOD Biotech PCL's Capex-to-Operating-Cash-Flow has ranged from 0.40 to 1.26. According to the industry distribution chart, DOD Biotech PCL ranks #999999 out of 1157 companies in the Consumer Packaged Goods industry.
Is DOD Biotech PCL's Capex-to-Operating-Cash-Flow too high?
DOD Biotech PCL's current Capex-to-Operating-Cash-Flow of 0.11 is 83% below median its 10-year median of 0.63. Over the past 10 years, this metric has ranged from a low of 0.40 to a high of 1.26. The Consumer Packaged Goods industry median Capex-to-Operating-Cash-Flow is 0.42. DOD Biotech PCL's value of 0.11 is 73.8% below this industry median. Based on the distribution chart, DOD Biotech PCL ranks #999999 out of 1157 companies in the Consumer Packaged Goods industry, which is in the bottom quartile relative to peers. Overall, DOD Biotech PCL has a GF Score™ of 67/100, reflecting its overall financial health beyond just this single metric.
How does DOD Biotech PCL's Capex-to-Operating-Cash-Flow compare to KHC and GIS?
According to the Consumer Packaged Goods industry distribution chart, DOD Biotech PCL ranks #999999 out of 1157 companies for Capex-to-Operating-Cash-Flow. This places DOD Biotech PCL in the lower half of its industry. The industry median Capex-to-Operating-Cash-Flow is 0.42. DOD Biotech PCL's value of 0.11 is 73.8% below this benchmark. Historically, DOD Biotech PCL's own Capex-to-Operating-Cash-Flow has ranged from 0.40 to 1.26 over the past decade. While the company's 10-year median is 0.63 vs. the industry median of 0.42, DOD Biotech PCL has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Capex-to-Operating-Cash-Flow for a Consumer Packaged Goods company?
The median Capex-to-Operating-Cash-Flow among Consumer Packaged Goods companies is 0.42, based on 1,157 companies in the industry. Companies in the top quartile (top 25%) have a Capex-to-Operating-Cash-Flow significantly above this median, while those in the bottom quartile fall well below. However, Capex-to-Operating-Cash-Flow should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. DOD Biotech PCL's current Capex-to-Operating-Cash-Flow of 0.11 is 73.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Capex-to-Operating-Cash-Flow mean?
A high Capex-to-Operating-Cash-Flow can signal that a stock is expensive relative to its fundamentals. Capex to Operating Cash Flow ratio assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. View historical data on DOD Biotech PCL and its competitors. For the Consumer Packaged Goods industry, the median Capex-to-Operating-Cash-Flow is 0.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DOD Biotech PCL's current Capex-to-Operating-Cash-Flow is 0.11, which is 83% below median its own 10-year median of 0.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DOD Biotech PCL stock overvalued right now?
DOD Biotech PCL (BKK:DOD-R) has a current Capex-to-Operating-Cash-Flow of 0.11. The stock's GF Value™ is ฿1.52, compared to a current price of ฿0.97 — trading 36.4% below its estimated fair value. The current Capex-to-Operating-Cash-Flow is 0.11, which is 83% below median its 10-year median of 0.63 and 73.8% below the Consumer Packaged Goods industry median of 0.42. DOD Biotech PCL's overall GF Score™ is 67/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Capex-to-Operating-Cash-Flow calculated?
Capex-to-Operating-Cash-Flow is calculated from a company's financial statements. For DOD Biotech PCL (BKK:DOD-R), the current Capex-to-Operating-Cash-Flow is 0.11 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is DOD Biotech PCL (BKK:DOD-R) Overvalued in 2026?
Based on GuruFocus' analysis, DOD Biotech PCL stock appears to be undervalued.
The current stock price of ฿0.97 is trading 36.4% below its estimated GF Value™ of ฿1.52.
Key valuation signals for BKK:DOD-R:
Capex-to-Operating-Cash-Flow: 0.11 (83% below median its 10-year median of 0.63)
GF Value™: ฿1.52 vs. price of ฿0.97 (36.4% below fair value)
Industry Position: 73.8% below the Consumer Packaged Goods median (#999999 of 1157)
No single metric tells the full story. See the BKK:DOD-R stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
DOD Biotech PCL is principally engaged in the manufacture and distribution of food supplements and health drinks of all kinds. The group is principally engaged in the supplement business. Its operations are carried on only in Thailand. Its products include: Capsule; Gel; Jelly; Powder for making drinks; Concentrated water extract (Shot Drink); Softgel; Tablet; Probiotics; Gummies; and Direct-to-Mouth Packaging.
67GF Score
Get the complete analysis for BKK:DOD-R
Capex-to-Operating-Cash-Flow is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:DOD-R has been successfully added to your 
